Interestingly, genetic alterations in PIK3CA have a strong tendency to coexist with PTEN deep deletion/mutation in patients with prostate cancer, and we have previously shown in mice that Pten homozygous deletion and an activating mutation in Pik3ca at H1047R synergize to promote prostate cancer progression and de novo CRPC [21]. This evidence concerns the gene PIK3CA and prostate cancer.